{"disease":{"id":"human-papillomavirus-hpv-16-relapsed-refractory-cancer","name":"human papillomavirus hpv 16 relapsed refractory cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03912831","title":"Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Gilead Sciences","has_results":true}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}